102 related articles for article (PubMed ID: 14532675)
1. Pergolide mesylate form II.
Jegorov A; Horák Z; Cejka J; Kratochvíl B; Císarová I
Acta Crystallogr C; 2003 Oct; 59(Pt 10):O575-6. PubMed ID: 14532675
[TBL] [Abstract][Full Text] [Related]
2. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.
Tintner R; Manian P; Gauthier P; Jankovic J
Arch Neurol; 2005 Aug; 62(8):1290-5. PubMed ID: 16087771
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A receptors.
Görnemann T; Hübner H; Gmeiner P; Horowski R; Latté KP; Flieger M; Pertz HH
J Pharmacol Exp Ther; 2008 Mar; 324(3):1136-45. PubMed ID: 18096760
[TBL] [Abstract][Full Text] [Related]
4. Multitemperature stability and degradation characteristics of pergolide mesylate oral liquid.
Shank BR; Ofner CM
J Pharm Pract; 2010 Dec; 23(6):570-4. PubMed ID: 21507864
[TBL] [Abstract][Full Text] [Related]
5. Pergolide mesylate in Parkinson's disease treatment.
Pezzoli G; Canesi M; Pesenti A; Mariani CB
J Neural Transm Suppl; 1995; 45():203-12. PubMed ID: 8748627
[TBL] [Abstract][Full Text] [Related]
6. Determination of pergolide in horse plasma by UPLC-MS/MS for pharmacokinetic applications.
Jacobson GA; Pirie A; Edwards S; Hughes KJ; Rendle DI; Davies NW
J Pharm Biomed Anal; 2014 Jun; 94():54-7. PubMed ID: 24549007
[TBL] [Abstract][Full Text] [Related]
7. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy.
Jankovic J
Neurology; 1983 Apr; 33(4):505-7. PubMed ID: 6339985
[TBL] [Abstract][Full Text] [Related]
8. Four products from the cyanoacetylation of pyrimidines: hydrogen-bonded dimers, pi-stacked hydrogen-bonded chains and hydrogen-bonded chains of edge-fused rings.
Trilleras J; Low JN; Cobo J; Marchal A; Glidewell C
Acta Crystallogr C; 2008 Mar; 64(Pt 3):o149-54. PubMed ID: 18322342
[TBL] [Abstract][Full Text] [Related]
9. Effect of pergolide mesylate, an ergoline, in animal models of Parkinson's disease: implications for therapy.
Koller WC; Diamond BI; Weiner WJ; Nausieda PA; Klawans HL
Trans Am Neurol Assoc; 1979; 104():161-4. PubMed ID: 553398
[No Abstract] [Full Text] [Related]
10. Effects of compounding and storage conditions on stability of pergolide mesylate.
Davis JL; Kirk LM; Davidson GS; Papich MG
J Am Vet Med Assoc; 2009 Feb; 234(3):385-9. PubMed ID: 19210262
[TBL] [Abstract][Full Text] [Related]
11. Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro.
Ono K; Hirohata M; Yamada M
J Neurosci Res; 2007 May; 85(7):1547-57. PubMed ID: 17387689
[TBL] [Abstract][Full Text] [Related]
12. [Sleep attacks and pergolide mesylate].
García Ruiz PJ; Hernández J; Cantarero S; Fanjul S
Neurologia; 2001 Feb; 16(2):92. PubMed ID: 11257938
[No Abstract] [Full Text] [Related]
13. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
Dewey RB; Reimold SC; O'Suilleabhain PE
Arch Neurol; 2007 Mar; 64(3):377-80. PubMed ID: 17353380
[TBL] [Abstract][Full Text] [Related]
14. Polymorphic form IV of olanzapine.
Thakuria R; Nangia A
Acta Crystallogr C; 2011 Nov; 67(Pt 11):o461-3. PubMed ID: 22051963
[TBL] [Abstract][Full Text] [Related]
15. Pergolide mesylate: its effects on circulating anterior pituitary hormones in man.
Perryman RL; Rogol AD; Kaiser DL; MacLeod RM; Thorner MO
J Clin Endocrinol Metab; 1981 Oct; 53(4):772-8. PubMed ID: 6793609
[TBL] [Abstract][Full Text] [Related]
16. Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up.
Pohanka M; Kanovský P; Bares M; Pulkrábek J; Rektor I
Eur J Neurol; 2004 Jul; 11(7):483-8. PubMed ID: 15257688
[TBL] [Abstract][Full Text] [Related]
17. Elevation of serum corticosterone in rats by dopamine agonists related in structure to pergolide.
Fuller RW; Snoddy HD; Mason NR; Clemens JA; Bemis KG
Neuroendocrinology; 1983; 36(4):285-90. PubMed ID: 6866215
[TBL] [Abstract][Full Text] [Related]
18. (5RS)-5-(4-Methoxyphenyl)-2-(methylsulfanyl)benzo[g]pyrimido[4,5-b]quinoline-4,6,11(3H,5H,12H)-trione, with Z' = 3, forms a three-dimensional hydrogen-bonded framework containing five types of hydrogen bond.
Castillo YA; Zapata LF; Trilleras J; Cobo J; Glidewell C
Acta Crystallogr C Struct Chem; 2014 Jan; 70(Pt 1):50-4. PubMed ID: 24399226
[TBL] [Abstract][Full Text] [Related]
19. 2-Methoxy-3-methyl-6-oxo-4-(2,3,4-tri-O-acetyl-beta-D-xylopyranosylamino)-1,6-dihydropyrimidine-5-carbaldehyde 0.065-hydrate and 2-methylsulfanyl-6-oxo-4-(2,3,4-tri-O-acetyl-beta-D-xylopyranosylamino)-1,6-dihydropyrimidine-5-carbaldehyde: hydrogen-bonded structures in one or three dimensions.
Cobo J; Nogueras M; de la Torre JM; Glidewell C
Acta Crystallogr C; 2009 Jul; 65(Pt 7):o321-5. PubMed ID: 19578264
[TBL] [Abstract][Full Text] [Related]
20. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
Eur J Pharmacol; 2015 Jan; 747():160-5. PubMed ID: 25499739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
